Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 4/20 | 0.52 |
| ▸ | ITGAV | P06756 | 4/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.52 |
| ▸ | ACACB | O00763 | 14/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4835350 | 0.90 | ITGB3 (0.60) | ITGB3ITGAVITGA2B | |
| SCHEMBL4918524 | 0.90 | ITGB3 (0.60) | ITGB3ITGAVITGA2B | |
| SCHEMBL5174657 | 0.89 | ITGB3 (0.52) | ITGB3ITGAVITGA2B | |
| SCHEMBL4832543 | 0.85 | ITGB3 (0.55) | ITGB3ITGAVITGA2B | |
| SCHEMBL8588059 | 0.84 | ITGB3 (0.47) | ITGB3ITGAVITGA2BALDH1A1 | |
| SCHEMBL7216246 | 0.84 | ITGB3 (0.64) | ITGB3ITGAVITGA2B | |
| SCHEMBL7218511 | 0.82 | ITGB3 (0.55) | ITGB3ITGAVITGA2BALDH1A1 | |
| SCHEMBL3370168 | 0.80 | ITGB3 (0.64) | ITGB3ITGAVITGA2B | |
| SCHEMBL14316415 | 0.79 | ACACB (0.42) | ACACBALDH1A1 | |
| SCHEMBL14253148 | 0.79 | ACACB (0.46) | ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348333-B2 | Cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | AVENTIS PHARMA S.A. (FR) | 2008-03-25 | — | — | US | disclosed |
| US-20080021055-A1 | Novel cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | AVENTIS PHARMA S.A. | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021055-A1 | Novel cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | ADGRF1, ADGRE5, CALCR | ITGB3 536/4885ITGAV 737/4885ITGA2B 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.